2. Search Result
Search Result
Results for "

QS 21

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

5

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101092
    QS-21-Api
    5 Publications Verification

    Stimulon

    		 NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    QS-21-Api, an immunostimulatory saponin, could be used as a potent vaccine adjuvant. QS-21-Api stimulates Th2 humoral and Th1 cell-mediated immune responses through action on antigen presenting cells (APCs) and T cells. QS-21-Api can activate the NLRP3 inflammasome with subsequent release of caspase-1 dependent cytokines, IL-1β and IL-18 .
    QS-21-Api
  • HY-101092A
    QS-21

    		Toll-like Receptor (TLR) Infection Cancer
    QS-21 is a mixture of QS-21-Xyl (250643-56-2) and QS-21-Api (141256-04-4), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria) .
    QS-21
  • HY-101092B
    QS-21-Xyl

    		Others Infection Cancer
    QS-21-Xyl is an immune system-targeted adjuvant, acting as an agonist for T-cell and B-cell immune responses. QS-21-Xyl enhances vaccine immunogenicity by activating dendritic cells and promoting antigen presentation. QS-21-Xyl is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria) .
    QS-21-Xyl
  • HY-N16463
    QS-S2

    		Drug Intermediate Others
    QS-S2 is the impurity of QS-21 (HY-101092A). QS-21 is a mixture of QS-21-Xyl (250643-56-2) and QS-21-Api (141256-04-4), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria) .
    QS-S2
  • HY-N15846
    VSA 1

    		Drug Derivative Infection Inflammation/Immunology
    VSA 1, a semisynthetic QS-21 (HY-101092) analog, is a saponin adjuvant. VSA 1 potentiates antigen-specific IgG1 and IgG2a immune responses in BALB/c mice, indicating a mixed Th1/Th2 immune response. VSA 1 significantly improves vaccine efficacy after primary immunization and enhances homologous protection .
    VSA 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: